Irbesartan 1 A Pharma

Irbesartan, the active ingredient in Irbesartan 1 A Pharma, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It is employed to manage high blood pressure and to protect kidney function in patients with diabetic kidney disease.

GNH USA supplies Irbesartan 1 A Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution.

Irbesartan is used to treat conditions related to the renin‑angiotensin system, primarily hypertension and diabetic kidney disease. - Hypertension: lowers elevated blood pressure, reducing cardiovascular risk. - Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes. - Proteinuria in diabetes: reduces urinary protein excretion, indicating renal protection.

Irbesartan may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain in the head region. - Fatigue: feeling unusually tired or weak. - Upper respiratory tract infection: symptoms such as sore throat or nasal congestion. - Hyperkalaemia: modest increase in blood potassium levels.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue or throat that may compromise breathing. - Acute renal failure: sudden decline in kidney function. - Severe hyperkalaemia: markedly elevated potassium that can affect heart rhythm. - Hepatic injury: signs of liver dysfunction such as jaundice or elevated enzymes.

When prescribing Irbesartan, clinicians should consider several safety measures. - Monitor blood pressure: ensure therapeutic reduction without excessive hypotension. - Assess renal function: check serum creatinine and eGFR before and during therapy. - Check serum potassium: especially in patients on potassium‑sparing agents. - Use caution in hepatic impairment: dose adjustment may be required. - Avoid in pregnancy: potential fetal toxicity. - Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Irbesartan can interact with other medicines, affecting its safety or effectiveness.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): combined use may increase risk of renal impairment and hyperkalaemia. - Potassium‑sparing diuretics or potassium supplements: may cause dangerous hyperkalaemia. - ACE inhibitors: concurrent use raises the risk of renal dysfunction and elevated potassium.

Moderate Interactions (Monitor Closely): - NSAIDs: can blunt antihypertensive effect and affect renal function. - Lithium: levels may rise, leading to toxicity. - Thiazide diuretics: may enhance hypotensive response and affect electrolyte balance.